The EU medicines regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's ability to slow cognitive ...

Eli Lilly on Thursday expanded its direct-to-consumer online platform LillyDirect to include telehealth providers to diagnose ...

A European regulatory committee has rejected Eli Lilly's U.S.-approved Alzheimer's disease treatment over potentially ...

Eli Lilly & Co. is adding Alzheimer’s disease resources to the online platform it launched a year ago to sell obesity, ...

A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...

Por THE ASSOCIATED PRESSUna comisión reguladora europea rechazó el tratamiento de Eli Lilly contra la enfermedad de Alzheimer ...

The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the risk of serious brain ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...

Eli Lilly is expanding its menu of direct-to-consumer healthcare offerings. | Eli Lilly is expanding its menu of ...

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...